Arix Bioscience participates in $80 million Series C financing for Autolus. Regulatory News Articles for Arix Bioscience Plc Ord 0.001P Fred Hutchinson Cancer Research Center is dedicated to the elimination of cancer and related diseases as causes of human suffering and death. Live ARIX RNS. Arix and Atlas Venture co-founded and seeded the company in 2018 along with co-founders Mark Tebbe, Ph.D., Chief Technology Officer, and Mike Nolan, Ph.D., Head of Biology, together with Arturo Zychlinsky and Herbert Waldmann, both Directors at The Max Planck Institute who collaborated with the Lead Discovery Center on inhibitors of NETosis and gasdermin. Experienced and collaborative team, with deep industry and scientific expertise. Download. While London South East do their best to maintain the high quality of the information displayed on this site, we cannot be held responsible for any loss due to incorrect information found here.

UCB is listed on Euronext Brussels (symbol: UCB). Hardman & Co Research: Arix Bioscience (ARIX): Realising the valuation disconnect, Arix Bioscience PLC: Autolus presents additional AUTO3 data in DLBCL, Arix Bioscience PLC: Interim Results for the Six Months Ended 30 June 2020, LogicBio announces IND clearance for LB-001, Atox Bio plans NDA submission for Q3 2020, VelosBio completes $137 million Series B financing, Director/PDMR Shareholding, Issue of Ordinary Shares, Aura presents updated AU-011 clinical data at ARVO 2020, Imara presents positive interim Phase 2a data at EHA, Arix announces strategic and operational update, Iterum announces topline Phase 3 data in complicated UTI, Harpoon presents interim Phase 1 data for HPN424, Autolus presents additional AUTO3 data in DLBCL, Amplyx closes $53 million Series C extension, Hardman & Co Research: Arix Bioscience (ARIX): 1Q'20 portfolio update, Pharmaxis announces new data in myelofibrosis, Harpoon doses first patient in multiple myeloma trial, Hardman & Co Research: Arix Bioscience (ARIX): Resetting the stage, Autolus announces FDA acceptance of IND application, Changes to Board of Directors and executive leadership, Hardman & Co Research: Arix Bioscience (ARIX): Fiscal 2019 - moving with the times, Annual Results for the year ended 31 December 2019, Update on Imara proposed IPO in the United States, Hardman & Co Research: Q&A with Q&A with Dr Dorothea Hill on Arix Bioscience (ARIX), Aura announces updated Phase 1b/2 clinical data, Hardman & Co Research: Arix Bioscience (ARIX) - Initiation of coverage: With high risk can come high reward, Imara files for proposed IPO in the United States, Autolus presents encouraging additional AUTO3 data, Arix co-founds Quench Bio with Series A financing, Autolus announces pricing of public offering, Iterum announces $52 million private placement. Click here to register. Download. Access Arix Bioscience plc shareholder documents including presentations, AGM, Corporate Governance and regulatory materials here. Arix has developed a wide network that includes pharma companies, research accelerators and universities. 26th September 2017. Through this network, Arix is able to identify new technologies and discoveries that provide a rich pipeline of potential investments. Quench Bio is named one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020, LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference, LogicBio Therapeutics to Present at the Jefferies Virtual Gene Editing/Therapy Summit, Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020, Arix Bioscience plc, registered in England and Wales with company number 09777975, Registered office: 20 Berkeley Square, London W1J 6EQ, United Kingdom. Fosun is a multinational company that has been listed on the main board of the Hong Kong Stock Exchange (00656.HK) since 2007. Updates from Arix and our porfolio companies. UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology or neurology. We apologise for the inconvenience. ARIX Resetting the stage 23 April 2020. Chief Operating Officer and General Counsel, Investment Team Assistant & Marketing Coordinator. The LDC seeks to advance promising research projects into the development of novel medicines, BioMotiv is a mission-driven pharmaceutical accelerator with a singular focus: through prevention and curative treatments accessible to all patients. Ipsen is a global biopharmaceutical group focused on innovation and specialty care. Unconstrained by institution, geography or stage of company development; we have the ability to source the best life science innovation without restriction. Find the latest share price, presentations, events and regulatory announcements here. Hand sanitizer and surface cleaner company Byotrol had a strong 2020 and are confident about 2021. Terms of Reference Nomination Committee Feb 2020. Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. monthly and annualsubscriptions available.